+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are conducting a Phase 2 randomized, double-masked, vehicle-controlled study to evaluate the safety and effectiveness of DFL24498 topical ophthalmic solution compared to a vehicle solution in adults with dry eye disease. Approximately 417 participants aged 18 years or older will be enrolled across multiple sites in the US. The study aims to understand how the treatment affects dry eye symptoms and eye health over 16 weeks. Participants will be randomly assigned to receive either DFL24498 or a vehicle solution, both administered as one drop in each eye four times daily for 12 weeks. The study includes three periods within the total 16 weeks, including treatment and follow-up phases. The treatments are applied topically to the eyes under controlled conditions to compare their effects. During the study, participants will undergo assessments such as corneal fluorescein staining using the National Eye Institute scale, symptom evaluations with the Symptom Assessment in Dry Eye questionnaire, tear production tests, and conjunctival staining. Safety will be monitored through reports of adverse events up to week 14. Visual acuity and other ocular measurements will be regularly checked to monitor treatment impact and participant health throughout the study.

Age: 18Years +All GendersPhase 2
24 locations
P

Actively Recruiting

Researchers are evaluating whether 225Ac-PSMA-617 AAA817 combined with androgen receptor pathway inhibitors ARPI prolongs radiographic progression-free survival rPFS compared to standard treatments in adult men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC. The study focuses on participants who have previously been treated with ARPI but not taxane chemotherapy or prior PSMA-targeting radioligand therapy in the mCRPC setting. This phase III, open-label, randomized study is conducted globally including the USA. Participants are randomly assigned to receive either up to six intravenous doses of AAA817 at 10 Megabecquerel MBq plus oral ARPI enzalutamide or abiraterone, or one of the standard care options chosen by investigators. Standard care options include switching ARPI, taxane-based chemotherapy docetaxel or cabazitaxel, or 177Lu-PSMA-617 AAA617 radioligand therapy. Treatment with ARPI continues per protocol until defined end of treatment criteria. Supportive care including androgen deprivation therapy is allowed in both groups. Crossover between groups is not permitted. Participants undergo screening to confirm eligibility including PSMA-positive status via PETCT scans. Throughout the study, safety assessments are performed regularly. Researchers will measure outcomes including radiographic progression-free survival up to approximately 40 months after randomization, as well as overall survival and other cancer progression markers. The study also monitors treatment responses, pain levels, and quality of life measures. Participants remain under observation for the duration of the study until the end date in 2032.

Age: 18Years - 100YearsMALEPhase 3
106 locations